A comprehensive meta-analysis of 51 randomized controlled trials published in Nature Medicine challenges a fundamental assumption in cardiovascular medicine: that prolonged antihypertensive therapy continuously amplifies cardiovascular protection. The analysis of individual participant data from tens of thousands of trial participants reveals that blood pressure-lowering benefits actually plateau by year four of treatment rather than compounding indefinitely.
This finding has significant implications for clinical practice, suggesting that clinicians may need to reconsider their approach to treatment duration and intensity. Rather than assuming longer therapy always equals greater protection, physicians should now focus on achieving target blood pressure early and reassessing individual treatment strategies based on these diminishing returns. The research underscores the importance of personalized hypertension management tailored to each patient’s unique cardiovascular risk profile.
Read the full article on GMJ Newsroom.
Was this article helpful?
